Centessa Pharmaceuticals plc ( CNTA ) released interim data from an ongoing Phase 1 trial of ORX750 in acutely sleep-deprived healthy volunteers.

ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated (1.0 mg and 2.5 mg) in the Maintenance of Wakefulness Test (MWT) compared to placebo.

MWT is a daytime sleep study that measures the ability to stay awake for a set period. It can help doctors evaluate how well the person responds to excessive sleepiness treatment.

The interim Phase 1 clinical data for ORX750 demonstrated:

Significantly increased wakefulness in acutely sleep-deprived healthy volunteers compared to placebo at both doses tested.

Treatment with ORX750 resulted in statistically significant (p